Print

Celsion Corporation (CLN) Reports First Quarter 2013 Financial Results and Provides Business Update  
5/9/2013 7:07:37 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LAWRENCEVILLE, N.J., May 9, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the first quarter ended March 31, 2013 and provided a business update on its clinical trials of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin.

Help employers find you! Check out all the jobs and post your resume.

//-->